Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 224

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 224
---
 NLS Board believes the Merger Agreement’s terms, including the Exchange Ratio, are 104 the most favorable achievable under the circumstances. In evaluating and approving the Merger Agreement and the transactions contemplated thereby, the Board considered a variety of factors, including the potential benefits and risks associated with the Merger. The Board did not assign relative or specific weights to the individual factors considered, and no single factor was determinative or outweighed any other factors in its decision. The decision of the Board to approve the Merger Agreement and the transactions contemplated thereby was made after considering the totality of the information presented and the overall expected benefits of the Merger. Kadimastem Board of Directors’ Reasons for the Merger In evaluating the Merger Agreement and the transactions it contemplates, the Kadimastem Board convened multiple meetings, engaged executive officers, legal counsel, and financial advisors, and analyzed significant information. The Kadimastem Board considered various factors that supported its decision to approve the Merger Agreement, including: Fairness and Valuation Reports •Fairness to Shareholders: Kadimastem’s fairness opinion concluded that the Exchange Ratio in the proposed Merger was fair, from a financial point of view, to Kadimastem. Strategic Synergies •Complementary Strengths: The combined expertise and product portfolio enhance the combined company’s ability to deliver comprehensive solutions. •Market Expansion: Operating in new geographies or market segments increases reach and diversification. •Strengthened Competitive Position: A larger entity is better equipped to navigate industry competition. Financial Benefits •Operational Efficiencies: Eliminating redundancies reduces costs and potentially increases profitability. •Growth Potential: Access to new revenue opportunities and markets strengthens the financial outlook. •Resource Consolidation: The Merger creates a more robust financial foundation. Advantages to Kadimastem Officers and Directors •Increased Value for Shares Held by Insiders: Increased value for shares held by insiders due to Nasdaq liquidity and valuation advantages. •Increased Credibility: Advantages of being Nasdaq -listedcompany and potential created from enhanced status. Innovation and Collaboration •Accelerated R&D: Sharing research and resources accelerates innovation in key areas, including diabetes. •Improved Product Development: Unified efforts enhance time -to-marketefficiency. Operational Strengths •Enhanced Infrastructure: Consolidation leads to improved technological and operational frameworks. •Stronger Workforce: Combining teams increases capacity and innovation potential. Competitive Landscape •Industry Leadership: Kadimastem believes that Merger positions the combined company